CS
ONC

Credit Suisse’s BeOne Medicines Ltd ONC Stock Holding History

Credit Suisse’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$453K Buy
2,895
+1,227
+74% +$198K ﹤0.01% 2678
2023
Q4 		$301K Sell
1,668
-243
-13% -$44K ﹤0.01% 2913
2023
Q3 		$344K Buy
1,911
+123
+7% +$24.3K ﹤0.01% 2880
2023
Q2 		$319K Sell
1,788
-138
-7% -$31.8K ﹤0.01% 2985
2023
Q1 		$415K Sell
1,926
-2,060
-52% -$494K ﹤0.01% 2843
2022
Q4 		$877K Sell
3,986
-75,481
-95% -$13.8M ﹤0.01% 2434
2022
Q3 		$10.7M Buy
79,467
+926
+1% +$159K 0.01% 878
2022
Q2 		$12.7M Sell
78,541
-36,927
-32% -$5.77M 0.01% 850
2022
Q1 		$21.8M Buy
115,468
+5,827
+5% +$1.24M 0.02% 735
2021
Q4 		$29.7M Buy
109,641
+16,727
+18% +$5.65M 0.02% 886
2021
Q3 		$33.7M Buy
92,914
+9,028
+11% +$2.95M 0.02% 819
2021
Q2 		$28.8M Buy
83,886
+3,404
+4% +$1.13M 0.02% 958
2021
Q1 		$28M Sell
80,482
-35,296
-30% -$11.7M 0.01% 986
2020
Q4 		$29.9M Buy
115,778
+26,352
+29% +$7.26M 0.01% 957
2020
Q3 		$25.6M Buy
89,426
+1,151
+1% +$271K 0.02% 900
2020
Q2 		$16.6M Sell
88,275
-12,586
-12% -$2.05M 0.01% 1039
2020
Q1 		$12.4M Sell
100,861
-6,287
-6% -$983K 0.01% 1075
2019
Q4 		$17.8M Buy
107,148
+21,517
+25% +$3.57M 0.01% 1099
2019
Q3 		$10.5M Sell
85,631
-5,357
-6% -$712K 0.01% 1278
2019
Q2 		$11.3M Buy
90,988
+7,141
+9% +$906K 0.01% 1240
2019
Q1 		$11.1M Sell
83,847
-32,895
-28% -$4.44M 0.01% 1180
2018
Q4 		$16.4M Buy
116,742
+61,721
+112% +$8.18M 0.02% 895
2018
Q3 		$9.48M Sell
55,021
-55,402
-50% -$9.32M 0.01% 1287
2018
Q2 		$17M Sell
110,423
-142,201
-56% -$25.4M 0.02% 936
2018
Q1 		$42.4M Sell
252,624
-115,005
-31% -$15.6M 0.04% 477
2017
Q4 		$35.9M Buy
367,629
+115,790
+46% +$10.6M 0.03% 567
2017
Q3 		$26.1M Buy
+251,839
New +$18.8M 0.03% 687
2017
Q1 		– Sell
-10,640
Closed -$323K – 4112
2016
Q4 		$323K Sell
10,640
-1,360
-11% -$42.7K ﹤0.01% 3627
2016
Q3 		$370K Buy
12,000
+1,000
+9% +$29K ﹤0.01% 3574
2016
Q2 		$328K Buy
+11,000
New +$323K ﹤0.01% 3656

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

Credit Suisse's ONC Position: Q1 2024 in Review

Credit Suisse increased its BeOne Medicines Ltd (ONC) stake by 74% in Q1 2024, buying an estimated $198K and bringing the position to 2,895 shares worth $453K. The position accounts for ﹤0.01% of the portfolio, ranked #2678.

Credit Suisse first reported a position in ONC in Q2 2016 and has held it in 30 quarters since. The position peaked at $42.4M in Q1 2018. 205 funds tracked by Wall St. Rank hold ONC as of Q1 2024.

  • Credit Suisse held 2,895 shares of BeOne Medicines Ltd worth $453K as of Q1 2024.
  • Credit Suisse bought 1,227 BeOne Medicines Ltd shares in Q1 2024, an estimated $198K.
  • BeOne Medicines Ltd made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2678 holding.
  • Credit Suisse first reported a position in BeOne Medicines Ltd in Q2 2016 and has held it in 30 quarters since.
  • Credit Suisse's BeOne Medicines Ltd position peaked at $42.4M in Q1 2018.
  • 205 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.